Cancer Vaccines
Return to Library
|
Free Cancer Vaccines Articles |
|
|
|
|
Findings from Y.X. Chen and co-authors provide new insights into cancer vaccines
2007 NOV 19 -- Fresh data on cancer are presented in the report 'A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10.' "The dendritic cell (DC)-based tumor immunotherapy has been a new promise of cure for cancer patients, but animal studies and clinical trials have thus far only shown limited success, especially in treating established tumors. Certain immunosuppressive mechanisms triggered by tumor cells or the derivatives are believed to be a major obstacle," investigators in People's Republic of China report. "We studied the role of DC-derived IL-10 and its negative impact on vaccine efficacy in mouse models. Liver tumor cells were injected via the portal vein, giving rise to disseminated intrahepatic tumors, or s.c. to form solid but extrahepatic tumors. Bone marrow-derived DCs were generated from normal or IL-10-deficient mice and used as the vector to deliver tumor Ags. We demonstrate here that DCs devoid of IL-10, a potent immunosuppressive cytokine, are superior over conventional DCs in triggering antitumor immunity. The IL-10(-/-)DCs were highly immunogenic, expressed enhanced levels of surface MHC class II molecules, and secreted increased amounts of Th1-related cytokines. By inducing tumor-specific killing and through the establishment of immunological memory, the vaccines delivered by IL-10(-/-)DCs could evoke strong therapeutic and protective immunity against hepatocellular carcinoma in the mouse models," wrote Y.X. Chen and colleagues, . The researchers concluded: "These findings will have great clinical impact once being translated into the treatment of malignant, and potentially infectious, diseases in humans." Chen and colleagues published their study in the Journal of Immunology (A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. Journal of Immunology, 2007;179(9):6009-15). For additional information, contact Y.X. Chen, University of Honk Kong, Dept. of Pathology, China. The publisher of the Journal of Immunology can be contacted at: American Association Immunologists, 9650 Rockville Pike, Bethesda, MD 20814, USA. Keywords: People's Republic of China, Angiology, Biological Therapy, Biotechnology, Bone, Cancer Vaccines, Clinical Trial Research, Hepatocellular Cancer, Hepatocellular Carcinoma, Immunology, Immunotherapy, Oncology, Portal Vein, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
